JP2008546754A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008546754A5 JP2008546754A5 JP2008517594A JP2008517594A JP2008546754A5 JP 2008546754 A5 JP2008546754 A5 JP 2008546754A5 JP 2008517594 A JP2008517594 A JP 2008517594A JP 2008517594 A JP2008517594 A JP 2008517594A JP 2008546754 A5 JP2008546754 A5 JP 2008546754A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- pyrazol
- chloro
- group
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxy, amino, methylamino, diethylamino Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000004432 carbon atom Chemical group C* 0.000 claims 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 14
- 229910052760 oxygen Inorganic materials 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 125000005647 linker group Chemical group 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 7
- 229910052731 fluorine Inorganic materials 0.000 claims 7
- 239000011737 fluorine Substances 0.000 claims 7
- 229940088597 hormone Drugs 0.000 claims 7
- 239000005556 hormone Substances 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004429 atom Chemical group 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 102000004127 Cytokines Human genes 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- IVDLDHJBOWQROZ-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-methyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNC)C1=CC=C(Cl)C=C1 IVDLDHJBOWQROZ-UHFFFAOYSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000002837 carbocyclic group Chemical group 0.000 claims 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 229960004641 rituximab Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- HWVGILTYGZFGLR-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CN)C1=CC=C(Cl)C=C1 HWVGILTYGZFGLR-UHFFFAOYSA-N 0.000 claims 3
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 3
- 108010069236 Goserelin Proteins 0.000 claims 3
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 3
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 229940123237 Taxane Drugs 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 3
- 229940127093 camptothecin Drugs 0.000 claims 3
- 229960004117 capecitabine Drugs 0.000 claims 3
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 3
- 229960003668 docetaxel Drugs 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229960002913 goserelin Drugs 0.000 claims 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 3
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 3
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims 3
- 229960002653 nilutamide Drugs 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 229960005079 pemetrexed Drugs 0.000 claims 3
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 3
- 150000003058 platinum compounds Chemical class 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 229960001727 tretinoin Drugs 0.000 claims 3
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 2
- SSRZUATVJOAMJJ-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)-[4-(1h-pyrazol-4-yl)phenyl]methyl]piperazine Chemical compound C1=C(Cl)C(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)N1CCNCC1 SSRZUATVJOAMJJ-UHFFFAOYSA-N 0.000 claims 2
- MGYPCCQLBPTNML-UHFFFAOYSA-N 1-[(4-chlorophenyl)-[4-(1h-pyrazol-4-yl)phenyl]methyl]piperazine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)N1CCNCC1 MGYPCCQLBPTNML-UHFFFAOYSA-N 0.000 claims 2
- HBYQXDUYJRDECS-UHFFFAOYSA-N 2-[[2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethyl]amino]ethanol Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNCCO)C1=CC=C(Cl)C=C1 HBYQXDUYJRDECS-UHFFFAOYSA-N 0.000 claims 2
- IIRWNGPLJQXWFJ-UHFFFAOYSA-N 2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)phenyl]ethanol Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(O)(CN)C1=CC=C(Cl)C=C1 IIRWNGPLJQXWFJ-UHFFFAOYSA-N 0.000 claims 2
- QLJLUDCLPSRPFI-UHFFFAOYSA-N 3-[[2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethyl]amino]propan-1-ol Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNCCCO)C1=CC=C(Cl)C=C1 QLJLUDCLPSRPFI-UHFFFAOYSA-N 0.000 claims 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 108010000817 Leuprolide Proteins 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229960002932 anastrozole Drugs 0.000 claims 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 229960000997 bicalutamide Drugs 0.000 claims 2
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960000255 exemestane Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 229960002258 fulvestrant Drugs 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 2
- 239000003667 hormone antagonist Substances 0.000 claims 2
- 229960003881 letrozole Drugs 0.000 claims 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 2
- BSDJRCSCDXPNOO-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(methylamino)-1-[4-(1h-pyrazol-4-yl)phenyl]ethanol Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(O)(CNC)C1=CC=C(Cl)C=C1 BSDJRCSCDXPNOO-UHFFFAOYSA-N 0.000 claims 1
- YPAHULZLTKIWQR-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CN1C=NC=C1 YPAHULZLTKIWQR-UHFFFAOYSA-N 0.000 claims 1
- HLVUQRHDBODCFJ-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethyl]piperazine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CN1CCNCC1 HLVUQRHDBODCFJ-UHFFFAOYSA-N 0.000 claims 1
- XGMBCVUAPHUSMA-UHFFFAOYSA-N 1-[2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CN1CCCCC1 XGMBCVUAPHUSMA-UHFFFAOYSA-N 0.000 claims 1
- FVHKVHULVJSUGS-UHFFFAOYSA-N 1-[3-(4-chlorophenyl)-3-[4-(1h-pyrazol-4-yl)phenyl]propyl]imidazole Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CCN1C=NC=C1 FVHKVHULVJSUGS-UHFFFAOYSA-N 0.000 claims 1
- YMOIUHMRAZGIKG-UHFFFAOYSA-N 1-[3-phenoxy-3-[4-(1h-pyrazol-4-yl)phenyl]propyl]imidazole Chemical compound C=1C=CC=CC=1OC(C=1C=CC(=CC=1)C1=CNN=C1)CCN1C=CN=C1 YMOIUHMRAZGIKG-UHFFFAOYSA-N 0.000 claims 1
- PVGMKLLGQDLGRJ-UHFFFAOYSA-N 1-methyl-4-[phenyl-[4-(1h-pyrazol-4-yl)phenyl]methyl]-1,4-diazepane Chemical compound C1CN(C)CCCN1C(C=1C=CC(=CC=1)C1=CNN=C1)C1=CC=CC=C1 PVGMKLLGQDLGRJ-UHFFFAOYSA-N 0.000 claims 1
- ALBNOJHFBUICLB-UHFFFAOYSA-N 1-phenyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=CC=CC=1C(N)CC(C=C1)=CC=C1C=1C=NNC=1 ALBNOJHFBUICLB-UHFFFAOYSA-N 0.000 claims 1
- YHDRFTQLBPOIDN-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(CN)C(C=C1)=CC=C1C=1C=NNC=1 YHDRFTQLBPOIDN-UHFFFAOYSA-N 0.000 claims 1
- KTCZKWVYZSCJKV-UHFFFAOYSA-N 2-(3-chloro-4-methoxyphenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C1=C(Cl)C(OC)=CC=C1C(CN)C1=CC=C(C2=CNN=C2)C=C1 KTCZKWVYZSCJKV-UHFFFAOYSA-N 0.000 claims 1
- YVVUEDSXVDPICU-UHFFFAOYSA-N 2-(3-chloro-4-methoxyphenyl)-n-methyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(OC)C(Cl)=CC=1C(CNC)C(C=C1)=CC=C1C=1C=NNC=1 YVVUEDSXVDPICU-UHFFFAOYSA-N 0.000 claims 1
- RZQSUNKASWLJQA-UHFFFAOYSA-N 2-(3-chlorophenoxy)-n-methyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNC)OC1=CC=CC(Cl)=C1 RZQSUNKASWLJQA-UHFFFAOYSA-N 0.000 claims 1
- JQAPAUAVUKTZPG-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-methyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=CC(Cl)=CC=1C(CNC)C(C=C1)=CC=C1C=1C=NNC=1 JQAPAUAVUKTZPG-UHFFFAOYSA-N 0.000 claims 1
- FSSABRHCBJFDJH-UHFFFAOYSA-N 2-(4-chloro-3-fluorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(Cl)C(F)=CC=1C(CN)C(C=C1)=CC=C1C=1C=NNC=1 FSSABRHCBJFDJH-UHFFFAOYSA-N 0.000 claims 1
- YTIXTVUIMQCOOX-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]acetamide Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(C(=O)N)C1=CC=C(Cl)C=C1 YTIXTVUIMQCOOX-UHFFFAOYSA-N 0.000 claims 1
- OQPBTDKODFFOER-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]morpholine Chemical compound C1=CC(Cl)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)OCCNC1 OQPBTDKODFFOER-UHFFFAOYSA-N 0.000 claims 1
- WJIBOVOTOYHIAY-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-fluoro-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(F)(CN)C1=CC=C(Cl)C=C1 WJIBOVOTOYHIAY-UHFFFAOYSA-N 0.000 claims 1
- KAPLTLJNVKHMLV-UHFFFAOYSA-N 2-(4-chlorophenyl)-n,n-dimethyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CN(C)C)C1=CC=C(Cl)C=C1 KAPLTLJNVKHMLV-UHFFFAOYSA-N 0.000 claims 1
- HGJXGKHMXZTCMI-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-(cyclopropylmethyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CNCC1CC1 HGJXGKHMXZTCMI-UHFFFAOYSA-N 0.000 claims 1
- HBXOAWAFHYIFMJ-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-ethyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNCC)C1=CC=C(Cl)C=C1 HBXOAWAFHYIFMJ-UHFFFAOYSA-N 0.000 claims 1
- UAALBJPKYVOYRB-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-methyl-2-[4-(1h-pyrazol-4-yl)phenyl]acetamide Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(C(=O)NC)C1=CC=C(Cl)C=C1 UAALBJPKYVOYRB-UHFFFAOYSA-N 0.000 claims 1
- YMBOWJASIPJHPL-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-methyl-2-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(C)(CNC)C1=CC=C(Cl)C=C1 YMBOWJASIPJHPL-UHFFFAOYSA-N 0.000 claims 1
- RQEUDJXTUCAVAA-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-methyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNC)C1=CC=C(F)C=C1 RQEUDJXTUCAVAA-UHFFFAOYSA-N 0.000 claims 1
- HNVSGFVICJTHBH-UHFFFAOYSA-N 2-(4-methoxyphenyl)-n-methyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNC)C1=CC=C(OC)C=C1 HNVSGFVICJTHBH-UHFFFAOYSA-N 0.000 claims 1
- VTNKIRBLRDIXRQ-UHFFFAOYSA-N 2-(methylamino)-1-(4-nitrophenyl)-1-[4-(1h-pyrazol-4-yl)phenyl]ethanol Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C(O)(CNC)C(C=C1)=CC=C1C=1C=NNC=1 VTNKIRBLRDIXRQ-UHFFFAOYSA-N 0.000 claims 1
- XNIAUSRAGOBQDX-UHFFFAOYSA-N 2-[(4-chlorophenyl)-[4-(1h-pyrazol-4-yl)phenyl]methoxy]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(OCCN)C1=CC=C(Cl)C=C1 XNIAUSRAGOBQDX-UHFFFAOYSA-N 0.000 claims 1
- NQEBEJVATHZQHM-UHFFFAOYSA-N 2-[3-(3,5-dimethyl-1h-pyrazol-4-yl)phenyl]-1-phenylethanamine Chemical compound CC1=NNC(C)=C1C1=CC=CC(CC(N)C=2C=CC=CC=2)=C1 NQEBEJVATHZQHM-UHFFFAOYSA-N 0.000 claims 1
- QBUGJWXOVSASPH-UHFFFAOYSA-N 2-[4-(3,5-dimethyl-1h-pyrazol-4-yl)phenyl]-2-phenylethanamine Chemical compound CC1=NNC(C)=C1C1=CC=C(C(CN)C=2C=CC=CC=2)C=C1 QBUGJWXOVSASPH-UHFFFAOYSA-N 0.000 claims 1
- PEVARZMNCRMKAQ-UHFFFAOYSA-N 2-[4-[2-(methylamino)-1-[4-(1h-pyrazol-4-yl)phenyl]ethyl]phenoxy]pyridine-4-carboxamide Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNC)C(C=C1)=CC=C1OC1=CC(C(N)=O)=CC=N1 PEVARZMNCRMKAQ-UHFFFAOYSA-N 0.000 claims 1
- QEHHLNLZIYNHFD-UHFFFAOYSA-N 2-[4-[4-[4-(1h-pyrazol-4-yl)phenyl]piperidin-4-yl]phenoxy]acetic acid Chemical compound C1=CC(OCC(=O)O)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 QEHHLNLZIYNHFD-UHFFFAOYSA-N 0.000 claims 1
- MWSMBSLUKDQMPK-UHFFFAOYSA-N 2-phenyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CN)C1=CC=CC=C1 MWSMBSLUKDQMPK-UHFFFAOYSA-N 0.000 claims 1
- GCIJUVFCSAIPKY-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(CCN)C(C=C1)=CC=C1C=1C=NNC=1 GCIJUVFCSAIPKY-UHFFFAOYSA-N 0.000 claims 1
- WBUYUGCRHOCOID-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-3-[4-(1h-pyrazol-4-yl)phenyl]propanamide Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(CC(=O)N)C(C=C1)=CC=C1C=1C=NNC=1 WBUYUGCRHOCOID-UHFFFAOYSA-N 0.000 claims 1
- CSPQEGYWLIIPIZ-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-3-[6-(1h-pyrazol-4-yl)pyridin-3-yl]propan-1-amine Chemical compound C=1C=C(Cl)C(Cl)=CC=1C(CCN)C(C=N1)=CC=C1C=1C=NNC=1 CSPQEGYWLIIPIZ-UHFFFAOYSA-N 0.000 claims 1
- MSRWMOWZENJWHN-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-n-methyl-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(F)C(F)=CC=1C(CCNC)C(C=C1)=CC=C1C=1C=NNC=1 MSRWMOWZENJWHN-UHFFFAOYSA-N 0.000 claims 1
- FGCYAZQVNZXMNP-UHFFFAOYSA-N 3-(3-chloro-4-methoxyphenyl)-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C1=C(Cl)C(OC)=CC=C1C(CCN)C1=CC=C(C2=CNN=C2)C=C1 FGCYAZQVNZXMNP-UHFFFAOYSA-N 0.000 claims 1
- PRHHLNJGKNRDQE-UHFFFAOYSA-N 3-(3-chloro-4-methoxyphenyl)-n-methyl-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(OC)C(Cl)=CC=1C(CCNC)C(C=C1)=CC=C1C=1C=NNC=1 PRHHLNJGKNRDQE-UHFFFAOYSA-N 0.000 claims 1
- XTCPRZFKMFVDJF-UHFFFAOYSA-N 3-(3-chlorophenoxy)-n-methyl-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CCNC)OC1=CC=CC(Cl)=C1 XTCPRZFKMFVDJF-UHFFFAOYSA-N 0.000 claims 1
- HEDXUHRIYXUKSI-UHFFFAOYSA-N 3-(3-chlorophenyl)-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=CC(Cl)=CC=1C(CCN)C(C=C1)=CC=C1C=1C=NNC=1 HEDXUHRIYXUKSI-UHFFFAOYSA-N 0.000 claims 1
- BLVZFJHSAUCMFX-UHFFFAOYSA-N 3-(3-chlorophenyl)-n-methyl-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=CC(Cl)=CC=1C(CCNC)C(C=C1)=CC=C1C=1C=NNC=1 BLVZFJHSAUCMFX-UHFFFAOYSA-N 0.000 claims 1
- PMSURQYNKZJHOA-UHFFFAOYSA-N 3-(4-chlorophenyl)-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CCN)C1=CC=C(Cl)C=C1 PMSURQYNKZJHOA-UHFFFAOYSA-N 0.000 claims 1
- NZKIKXUXRVDQAK-UHFFFAOYSA-N 3-(4-chlorophenyl)-3-[4-(1h-pyrazol-4-yl)phenyl]propanamide Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CC(=O)N)C1=CC=C(Cl)C=C1 NZKIKXUXRVDQAK-UHFFFAOYSA-N 0.000 claims 1
- MLWHKTLBRHPGGV-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-methyl-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CCNC)C1=CC=C(Cl)C=C1 MLWHKTLBRHPGGV-UHFFFAOYSA-N 0.000 claims 1
- PMQWUCJKVOBNEE-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-methyl-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CCNC)C1=CC=C(F)C=C1 PMQWUCJKVOBNEE-UHFFFAOYSA-N 0.000 claims 1
- DXCGBCQOMLIHOA-UHFFFAOYSA-N 3-(4-methoxyphenyl)-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C1=CC(OC)=CC=C1C(CCN)C1=CC=C(C2=CNN=C2)C=C1 DXCGBCQOMLIHOA-UHFFFAOYSA-N 0.000 claims 1
- SAJGJQMGFRPHDO-UHFFFAOYSA-N 3-(4-phenoxyphenyl)-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CCN)C(C=C1)=CC=C1OC1=CC=CC=C1 SAJGJQMGFRPHDO-UHFFFAOYSA-N 0.000 claims 1
- VRICFPVOFWNRLE-UHFFFAOYSA-N 3-phenyl-2-[3-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=CC(C2=CNN=C2)=CC=1C(CN)CC1=CC=CC=C1 VRICFPVOFWNRLE-UHFFFAOYSA-N 0.000 claims 1
- ZJEQGMQJPQNZJK-UHFFFAOYSA-N 3-phenyl-2-[3-(1h-pyrazol-4-yl)phenyl]propanenitrile Chemical compound C=1C=CC(C2=CNN=C2)=CC=1C(C#N)CC1=CC=CC=C1 ZJEQGMQJPQNZJK-UHFFFAOYSA-N 0.000 claims 1
- GNOJHSRNZXLFFX-UHFFFAOYSA-N 3-phenyl-2-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CN)CC1=CC=CC=C1 GNOJHSRNZXLFFX-UHFFFAOYSA-N 0.000 claims 1
- USUVTKQVEFVSHN-UHFFFAOYSA-N 4-(2-chloro-3-fluorophenyl)-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine Chemical compound FC1=CC=CC(C2(CCNCC2)C=2C=CC(=CC=2)C2=CNN=C2)=C1Cl USUVTKQVEFVSHN-UHFFFAOYSA-N 0.000 claims 1
- MHPPVGSDNKCZMG-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 MHPPVGSDNKCZMG-UHFFFAOYSA-N 0.000 claims 1
- LQLAOBTZZLDUJD-UHFFFAOYSA-N 4-(3-chloro-4-methoxyphenyl)-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine Chemical compound C1=C(Cl)C(OC)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 LQLAOBTZZLDUJD-UHFFFAOYSA-N 0.000 claims 1
- YLEMKLICYJNLDA-UHFFFAOYSA-N 4-(4-chloro-3-fluorophenyl)-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine Chemical compound C1=C(Cl)C(F)=CC(C2(CCNCC2)C=2C=CC(=CC=2)C2=CNN=C2)=C1 YLEMKLICYJNLDA-UHFFFAOYSA-N 0.000 claims 1
- JBBMHGJGPVSWOO-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-methyl-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine Chemical compound C1CN(C)CCC1(C=1C=CC(=CC=1)C1=CNN=C1)C1=CC=C(Cl)C=C1 JBBMHGJGPVSWOO-UHFFFAOYSA-N 0.000 claims 1
- GVBDZLGRVUJEFW-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-[4-(5-methyl-1h-pyrazol-4-yl)phenyl]piperidine Chemical compound CC1=NNC=C1C1=CC=C(C2(CCNCC2)C=2C=CC(Cl)=CC=2)C=C1 GVBDZLGRVUJEFW-UHFFFAOYSA-N 0.000 claims 1
- PYVKMDJDKCKVJO-UHFFFAOYSA-N 4-(4-methoxyphenyl)-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine Chemical compound C1=CC(OC)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 PYVKMDJDKCKVJO-UHFFFAOYSA-N 0.000 claims 1
- HGHCXFKOUIZYGF-UHFFFAOYSA-N 4-[2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethyl]morpholine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CN1CCOCC1 HGHCXFKOUIZYGF-UHFFFAOYSA-N 0.000 claims 1
- PAJNBJLDVKJXNX-UHFFFAOYSA-N 4-[3-(methylamino)-1-[4-(1h-pyrazol-4-yl)phenyl]propyl]phenol Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CCNC)C1=CC=C(O)C=C1 PAJNBJLDVKJXNX-UHFFFAOYSA-N 0.000 claims 1
- WZTPTWWAPVMONU-UHFFFAOYSA-N 4-[4-(2-methoxyethoxy)phenyl]-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine Chemical compound C1=CC(OCCOC)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 WZTPTWWAPVMONU-UHFFFAOYSA-N 0.000 claims 1
- IQTMZQRPCUSIKL-UHFFFAOYSA-N 4-[4-(3,5-dimethyl-1h-pyrazol-4-yl)phenyl]-4-phenylpiperidine Chemical compound CC1=NNC(C)=C1C1=CC=C(C2(CCNCC2)C=2C=CC=CC=2)C=C1 IQTMZQRPCUSIKL-UHFFFAOYSA-N 0.000 claims 1
- JDQHJOPZQIJCEA-UHFFFAOYSA-N 4-[4-(3-methoxypropoxy)phenyl]-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine Chemical compound C1=CC(OCCCOC)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 JDQHJOPZQIJCEA-UHFFFAOYSA-N 0.000 claims 1
- HLBRXOVHXRAVBQ-UHFFFAOYSA-N 4-[4-[1-(4-chlorophenyl)-2-pyrrolidin-1-ylethyl]phenyl]-1h-pyrazole Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CN1CCCC1 HLBRXOVHXRAVBQ-UHFFFAOYSA-N 0.000 claims 1
- JJMWTFLOALEUFK-UHFFFAOYSA-N 4-[4-[1-(4-chlorophenyl)-3-pyrrolidin-1-ylpropyl]phenyl]-1h-pyrazole Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CCN1CCCC1 JJMWTFLOALEUFK-UHFFFAOYSA-N 0.000 claims 1
- LMQVASLLHRUDEK-UHFFFAOYSA-N 4-[4-[2-(azetidin-1-yl)-1-(4-chlorophenoxy)ethyl]phenyl]-1h-pyrazole Chemical compound C1=CC(Cl)=CC=C1OC(C=1C=CC(=CC=1)C1=CNN=C1)CN1CCC1 LMQVASLLHRUDEK-UHFFFAOYSA-N 0.000 claims 1
- GXIKHGUANWIUPY-UHFFFAOYSA-N 4-[4-[2-(azetidin-1-yl)-1-(4-chlorophenyl)ethyl]phenyl]-1h-pyrazole Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CN1CCC1 GXIKHGUANWIUPY-UHFFFAOYSA-N 0.000 claims 1
- PEEKZDAJUZOSLT-UHFFFAOYSA-N 4-[4-[3-(azetidin-1-yl)-1-(4-chlorophenyl)propyl]phenyl]-1h-pyrazole Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC(=CC=1)C1=CNN=C1)CCN1CCC1 PEEKZDAJUZOSLT-UHFFFAOYSA-N 0.000 claims 1
- VBIDRMWBZZTFRK-UHFFFAOYSA-N 4-[4-[4-(1h-pyrazol-4-yl)phenyl]piperidin-4-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 VBIDRMWBZZTFRK-UHFFFAOYSA-N 0.000 claims 1
- PBNKBTUXTSOMLR-UHFFFAOYSA-N 4-[4-[4-(1h-pyrazol-4-yl)phenyl]piperidin-4-yl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 PBNKBTUXTSOMLR-UHFFFAOYSA-N 0.000 claims 1
- AOJCEFPPEOPJAD-UHFFFAOYSA-N 4-[4-[4-(1h-pyrazol-4-yl)phenyl]piperidin-4-yl]phenol Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 AOJCEFPPEOPJAD-UHFFFAOYSA-N 0.000 claims 1
- HQMWZYTXIFWKPY-UHFFFAOYSA-N 4-[4-[4-(4-chlorophenyl)piperidin-4-yl]phenyl]-1h-pyrazole-5-carbonitrile Chemical compound C1=CC(Cl)=CC=C1C1(C=2C=CC(=CC=2)C=2C(=NNC=2)C#N)CCNCC1 HQMWZYTXIFWKPY-UHFFFAOYSA-N 0.000 claims 1
- LKFDJWGYWDCRPC-UHFFFAOYSA-N 4-phenyl-4-[4-(1h-pyrazol-4-yl)phenyl]piperidine Chemical compound C1CNCCC1(C=1C=CC(=CC=1)C1=CNN=C1)C1=CC=CC=C1 LKFDJWGYWDCRPC-UHFFFAOYSA-N 0.000 claims 1
- LZMOSYUFVYJEPY-UHFFFAOYSA-N AT7867 Chemical compound C1=CC(Cl)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 LZMOSYUFVYJEPY-UHFFFAOYSA-N 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- 102000013135 CD52 Antigen Human genes 0.000 claims 1
- 108010065524 CD52 Antigen Proteins 0.000 claims 1
- 229940096395 DNA methylase inhibitor Drugs 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 229940079131 Methylase inhibitor Drugs 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- 229960004338 leuprorelin Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- DFDZKFAFULTKDV-UHFFFAOYSA-N methyl 2-[4-[4-[4-(1h-pyrazol-4-yl)phenyl]piperidin-4-yl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C1(C=2C=CC(=CC=2)C2=CNN=C2)CCNCC1 DFDZKFAFULTKDV-UHFFFAOYSA-N 0.000 claims 1
- 125000006518 morpholino carbonyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])N(C(*)=O)C1([H])[H] 0.000 claims 1
- RUGFXXKVNXNFGY-UHFFFAOYSA-N n,n-dimethyl-2,2-bis[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CN(C)C)C(C=C1)=CC=C1C=1C=NNC=1 RUGFXXKVNXNFGY-UHFFFAOYSA-N 0.000 claims 1
- PJCLMNOZUMMYTJ-UHFFFAOYSA-N n,n-dimethyl-2-phenyl-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CN(C)C)C1=CC=CC=C1 PJCLMNOZUMMYTJ-UHFFFAOYSA-N 0.000 claims 1
- KMBPALGRPXPTJC-UHFFFAOYSA-N n,n-dimethyl-3-[4-(1h-pyrazol-4-yl)phenyl]-3-pyridin-2-ylpropan-1-amine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C(C=C1)=CC=C1C=1C=NNC=1 KMBPALGRPXPTJC-UHFFFAOYSA-N 0.000 claims 1
- YCAFDYGANIWYNW-UHFFFAOYSA-N n,n-dimethyl-4-[3-(methylamino)-1-[4-(1h-pyrazol-4-yl)phenyl]propyl]aniline Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CCNC)C1=CC=C(N(C)C)C=C1 YCAFDYGANIWYNW-UHFFFAOYSA-N 0.000 claims 1
- RLUISSQWDGXBRY-UHFFFAOYSA-N n-[2-(4-chlorophenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethyl]propan-2-amine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNC(C)C)C1=CC=C(Cl)C=C1 RLUISSQWDGXBRY-UHFFFAOYSA-N 0.000 claims 1
- IGGFWLLVYRWCCO-UHFFFAOYSA-N n-methyl-2,2-bis[4-(1h-pyrazol-4-yl)phenyl]acetamide Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(C(=O)NC)C(C=C1)=CC=C1C=1C=NNC=1 IGGFWLLVYRWCCO-UHFFFAOYSA-N 0.000 claims 1
- BOLSKJHQKNEEIZ-UHFFFAOYSA-N n-methyl-2,2-bis[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNC)C(C=C1)=CC=C1C=1C=NNC=1 BOLSKJHQKNEEIZ-UHFFFAOYSA-N 0.000 claims 1
- GDKGYPHOFSWULD-UHFFFAOYSA-N n-methyl-2-(4-phenoxyphenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNC)C(C=C1)=CC=C1OC1=CC=CC=C1 GDKGYPHOFSWULD-UHFFFAOYSA-N 0.000 claims 1
- AVMYSWGHPQZPKK-UHFFFAOYSA-N n-methyl-2-(4-pyrazin-2-yloxyphenyl)-2-[4-(1h-pyrazol-4-yl)phenyl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)C=CC=1C(CNC)C(C=C1)=CC=C1OC1=CN=CC=N1 AVMYSWGHPQZPKK-UHFFFAOYSA-N 0.000 claims 1
- DKDQKBGMSVFFGE-UHFFFAOYSA-N n-methyl-2-[4-(1h-pyrazol-4-yl)phenyl]-2-(4-pyridin-3-ylphenyl)ethanamine Chemical compound C=1C=C(C=2C=NC=CC=2)C=CC=1C(CNC)C(C=C1)=CC=C1C=1C=NNC=1 DKDQKBGMSVFFGE-UHFFFAOYSA-N 0.000 claims 1
- PGDUARZFLYYKNP-UHFFFAOYSA-N n-methyl-2-phenyl-2-[6-(1h-pyrazol-4-yl)pyridin-3-yl]ethanamine Chemical compound C=1C=C(C2=CNN=C2)N=CC=1C(CNC)C1=CC=CC=C1 PGDUARZFLYYKNP-UHFFFAOYSA-N 0.000 claims 1
- GSCXAIQOLGKSEW-UHFFFAOYSA-N n-methyl-3-naphthalen-2-yl-3-[4-(1h-pyrazol-4-yl)phenyl]propan-1-amine Chemical compound C=1C=C2C=CC=CC2=CC=1C(CCNC)C(C=C1)=CC=C1C=1C=NNC=1 GSCXAIQOLGKSEW-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 0 **(*c1c(*)[n]nc1*)N(*)* Chemical compound **(*c1c(*)[n]nc1*)N(*)* 0.000 description 5
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69330905P | 2005-06-23 | 2005-06-23 | |
| US69336705P | 2005-06-23 | 2005-06-23 | |
| US69349205P | 2005-06-23 | 2005-06-23 | |
| US69331505P | 2005-06-23 | 2005-06-23 | |
| US69331405P | 2005-06-23 | 2005-06-23 | |
| US60/693,492 | 2005-06-23 | ||
| US60/693,315 | 2005-06-23 | ||
| US60/693,314 | 2005-06-23 | ||
| US60/693,367 | 2005-06-23 | ||
| US60/693,309 | 2005-06-23 | ||
| PCT/GB2006/002297 WO2006136837A2 (en) | 2005-06-23 | 2006-06-21 | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008546754A JP2008546754A (ja) | 2008-12-25 |
| JP2008546754A5 true JP2008546754A5 (https=) | 2009-08-06 |
| JP5345842B2 JP5345842B2 (ja) | 2013-11-20 |
Family
ID=37453306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008517594A Expired - Fee Related JP5345842B2 (ja) | 2005-06-23 | 2006-06-21 | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8541461B2 (https=) |
| EP (1) | EP1933832A2 (https=) |
| JP (1) | JP5345842B2 (https=) |
| WO (1) | WO2006136837A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1465863B1 (en) | 2002-01-04 | 2008-07-09 | NeuroSearch A/S | Potassium channel modulators |
| BRPI0418078A8 (pt) | 2003-12-23 | 2018-01-02 | Astex Therapeutics Ltd | composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto |
| EP1902032A1 (en) | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5345842B2 (ja) | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
| US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
| US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2008098105A1 (en) * | 2007-02-07 | 2008-08-14 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| GB0704932D0 (en) * | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP2303852A4 (en) * | 2008-06-26 | 2011-12-28 | Glaxosmithkline Llc | ACTIVITY INHIBITORS AKT |
| US8389731B2 (en) * | 2009-05-15 | 2013-03-05 | Northwestern University | Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| US9688682B2 (en) | 2013-07-16 | 2017-06-27 | Dr. Reddy's Laboratories Limited | Crystalline forms of pemetrexed tromethamine salts |
| SMT202500389T1 (it) | 2018-12-28 | 2025-11-10 | Deciphera Pharmaceuticals Llc | Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti |
| US20250206720A1 (en) | 2023-12-08 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Solid forms of an ulk inhibitor |
| WO2025122952A1 (en) | 2023-12-08 | 2025-06-12 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| WO2025231106A1 (en) | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2046628A1 (en) | 1989-02-08 | 1990-08-09 | Dee W. Brooks | 4-hydroxythiazoles as 5-lipoxygenase inhibitors |
| US5049570A (en) | 1990-01-23 | 1991-09-17 | Du Pont Merck Pharmaceutical Company | Pyridylphenyl nitrogen heterocycle-substituted carbinols and derivatives thereof with anti-inflammatory activity |
| FR2707295A1 (fr) | 1993-06-07 | 1995-01-13 | Rhone Poulenc Agrochimie | Fongicides pyrazoles substitués en position 3 par un hétérocycle. |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US5532356A (en) | 1995-06-06 | 1996-07-02 | The Dupont Merck Pharmaceutical Company | Method for preparing N,N'-disubstituted cyclic ureas |
| GB9512961D0 (en) | 1995-06-26 | 1995-08-30 | Pfizer Ltd | Antifungal agents |
| JP2000507593A (ja) | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質トランスフェラーゼ阻害剤 |
| GB2339298B (en) | 1996-04-30 | 2000-05-10 | Eastman Kodak Co | Use of pyrazolone image dye-forming couplers for enhancing light stability |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| GB9700555D0 (en) | 1997-01-13 | 1997-03-05 | Merck Sharp & Dohme | Therapeutic agents |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
| AU759772B2 (en) | 1998-01-29 | 2003-05-01 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| GB9804734D0 (en) | 1998-03-05 | 1998-04-29 | Pfizer Ltd | Compounds |
| WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
| HN1999000149A (es) | 1998-09-09 | 2000-01-12 | Pfizer Prod Inc | Derivados de 4,4-biarilpiperidina |
| US6503905B1 (en) | 1998-12-29 | 2003-01-07 | Pfizer Inc | 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives |
| AU4308300A (en) | 1999-05-03 | 2000-11-17 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
| CA2372044A1 (en) | 1999-05-14 | 2000-11-23 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| DE60040676D1 (de) | 1999-09-17 | 2008-12-11 | Millennium Pharm Inc | BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa |
| JP2003509412A (ja) | 1999-09-17 | 2003-03-11 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子阻害剤 |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| IL136458A0 (en) | 2000-05-30 | 2001-06-14 | Peptor Ltd | Protein kinase inhibitors |
| US6511994B2 (en) | 2000-10-11 | 2003-01-28 | Merck & Co., Inc. | Modulators of CCR5 chemokine receptor activity |
| WO2002088090A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
| DE60226154T2 (de) | 2001-08-03 | 2009-05-20 | Vertex Pharmaceuticals Inc., Cambridge | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
| FR2830192B1 (fr) | 2001-09-28 | 2004-08-20 | Oreal | Composition tinctoriale comprenant une base d'oxydation du type diaminopyrazole et un coupleur pyrazolo-azole |
| AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| WO2003059884A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| RS52392B (sr) | 2002-02-14 | 2013-02-28 | Pharmacia Corporation | Supstituisani piridinoni kao modulatori p38 map kinaze |
| CA2479338A1 (en) | 2002-03-20 | 2003-10-02 | Metabolex, Inc. | Substituted phenylacetic acids |
| ES2575354T3 (es) | 2002-04-08 | 2016-06-28 | Boston Scientific Scimed, Inc. | Dispositivos y procedimientos de saciedad |
| AU2003223708A1 (en) | 2002-04-23 | 2003-11-10 | Axys Pharmaceuticals, Inc. | Novel phenyl derivatives as inducers of apoptosis |
| ES2385378T3 (es) | 2002-07-24 | 2012-07-24 | Dermira (Canada), Inc. | Derivados de pirazolilbenzotiazol y su uso como agentes terapéuticos |
| CA2498046A1 (en) * | 2002-09-18 | 2004-04-01 | The Curators Of The University Of Missouri | Opiate analogs selective for the delta-opioid receptor |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
| CA2530389A1 (en) | 2003-07-02 | 2005-01-13 | Biofocus Discovery Limited | Pyrazine and pyridine derivatives as rho kinase inhibitors |
| PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| EP2468729B1 (en) | 2003-10-15 | 2013-12-25 | Ube Industries, Ltd. | Novel indazole derivative |
| US20050192314A1 (en) | 2003-11-13 | 2005-09-01 | Ambit Biosciences Corporation | Urea derivatives as C-kit modulators |
| BRPI0418078A8 (pt) * | 2003-12-23 | 2018-01-02 | Astex Therapeutics Ltd | composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| CA2590961C (en) | 2004-12-28 | 2013-11-26 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| US7423043B2 (en) | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| GB2427406A (en) | 2005-06-21 | 2006-12-27 | Astex Technology Ltd | Silicon-containing PKB/PKA kinase inhibitors |
| UY29610A1 (es) | 2005-06-21 | 2007-01-31 | Cancer Rec Tech Ltd | Aril-alquilaminas y heteroaril-alquilaminas como inhibidores de la quinasa proteínica |
| JP2008543919A (ja) | 2005-06-21 | 2008-12-04 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
| EP1902032A1 (en) | 2005-06-22 | 2008-03-26 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5345842B2 (ja) | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
-
2006
- 2006-06-21 JP JP2008517594A patent/JP5345842B2/ja not_active Expired - Fee Related
- 2006-06-21 WO PCT/GB2006/002297 patent/WO2006136837A2/en not_active Ceased
- 2006-06-21 US US11/993,823 patent/US8541461B2/en not_active Expired - Fee Related
- 2006-06-21 EP EP06755597A patent/EP1933832A2/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008546754A5 (https=) | ||
| HRP20100675T1 (hr) | Derivati pirazola kao modulatori protein kinaze | |
| RU2017104918A (ru) | СОЛЬ ПРИСОЕДИНЕНИЯ КИСЛОТЫ СОЕДИНЕНИЯ, ИНГИБИРУЮЩЕГО Trk | |
| Patnaik et al. | A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors | |
| JP2008546751A5 (https=) | ||
| NZ601794A (en) | Di - substituted pyridine derivatives as anticancers | |
| RU2004117545A (ru) | Аминопиримидины и пиридины | |
| CY1126060T1 (el) | Αντιπολλαπλασιαστικες ενωσεις και διειδικο αντισωμα εναντι bcma και cd3 για συνδυασμενη χρηση | |
| JP2013518129A5 (https=) | ||
| JP2007523182A5 (https=) | ||
| JP2007509117A5 (https=) | ||
| JP2010534654A5 (https=) | ||
| JP2012530765A5 (https=) | ||
| JP2013507351A5 (https=) | ||
| JP2016535772A5 (https=) | ||
| KR950704271A (ko) | 비시클릭 피브리노겐 길항제(Bicyclic Fibrinogen Antagonists) | |
| RU2007139634A (ru) | Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения | |
| NZ591427A (en) | P38 map kinase inhibitors | |
| JP2008528471A5 (https=) | ||
| JP2014529612A5 (https=) | ||
| EA023517B1 (ru) | Модуляторы глюкагонового рецептора | |
| JP2016513660A5 (https=) | ||
| JP2013530240A5 (https=) | ||
| JP2011502956A5 (https=) | ||
| RU2017103753A (ru) | Производное пиридона, имеющее тетрагидропиранилметильную группу |